-
1
BRD4 silencing attenuates hemin-induced neuronal ferroptosis and inflammation via the H3K27ac–ATF3 axis in an in vitro model of cerebral hemorrhage
Published 2025-07-01Subjects: Get full text
Article -
2
MYC Binding Near Transcriptional End Sites Regulates Basal Gene Expression, Read‐Through Transcription, and Intragenic Contacts
Published 2025-08-01Subjects: “…BRD4…”
Get full text
Article -
3
Bromodomain-containing protein 4 contributes to chronic postsurgical pain via activating TLR4/NF-kappaB-dependent neuroinflammation
Published 2025-07-01Subjects: Get full text
Article -
4
The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer
Published 2019-09-01Subjects: “…BRD4…”
Get full text
Article -
5
(+)-JQ-1 alleviates cardiac injury in myocardial infarction by inhibiting ferroptosis through the NAMPT/SIRT1 pathway
Published 2025-07-01“…Bromodomain-containing protein 4 (BRD4) is an epigenetic reader and a key regulator of cell survival. …”
Get full text
Article -
6
SPATIO-TEMPORAL ORGANIZATION OF THE SUPER-ENHANCER STRUCTURE IN CANCER CELLS
Published 2025-08-01“…Mass spectrometry revealed the RNA-dependent PIP2-associated (RDPA) nuclear proteome, enriched for intrinsically disordered regions and polybasic motifs, supporting LLPS. Among RDPA proteins, BRD4 undergoes PIP2- and RNA-dependent condensation. …”
Get full text
Article -
7
A methyl-to-acetyl switch in H3K27 drives metabolic reprogramming and resistance to BRAFV600E inhibition in melanoma
Published 2025-10-01“…This H3K27 methyl-to-acetyl conversion shifts chromatin from a repressive to an active state, thereby promoting gene transcription through the acetylation reader BRD4. Specifically, the KDM6A-H3K27ac-BRD4 axis upregulates PGC1α, a master regulator of mitochondrial metabolism, enabling melanoma cells to sustain oxidative metabolism and survive BRAFV600E-targeted therapies. …”
Get full text
Article -
8
Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress
Published 2025-09-01“…Recent progress in developing KEAP1-based PROTACs targeting BRD4, CDK9, FAK, Tau and KEAP1 itself is highlighted, with particular emphasis on ligand optimization strategies employed to enhance degradation efficacy and specificity. …”
Get full text
Article